Nanobiotix Appoints Bernd Muehlenweg as a Member of the Executive Board

26-Apr-2012 - France

Nanobiotix announced it has appointed Dr. Bernd Muehlenweg, currently “Head of Business Development” as a member of the Executive Board in support of the future growth of Nanobiotix.

Bernd Mühlenweg joined Nanobiotix in 2011 as Head of Business Development. From 2001 to 2011, he had been Director Business Development of oncology company WILEX AG (Munich, Germany), where he played a key role in the negotiation and execution of several license and commercialization agreements with pharma companies and in alliance management. He is a member of the Pharma Licensing Club of Germany (Pharmalizenzclub) and of the Pharma Licensing Club France.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances